A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Clinical trial NCT03512197 · COMPLETED
Trial details
- NCT number
- NCT03512197
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-20
- Primary completion
- 2021-02-12
- Enrollment
- 511
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.